SURPASS-ET: Ropeginterferon alfa-2b demonstrates superior efficacy over anagrelide in high-risk essential thrombocythemia

Myeloproliferative Neoplasms (MPNs)

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study

Lancet Haematol

Mesa R, Gill H, Zhang L, Jin J, Kirito K, Komatsu N, Qin A, Xiao Z, Tashi T, Shimoda K, Ohishi K, Chen S, Zuo X, Shirane S, Hu Y, Zhang S, Wang Y, Takenaka K, Ichii M, Xu N, Shih LY, Lim KH, Lee SE, Bae SH, Teo WZY, Maze D, Oh ST, Bose P, Sato T, Zagrijtschuk O, Lin S, Shih WJ, Mascarenhas J, Masarova L, SURPASS-ET Study Group

doi: 10.1016/S2352-3026(25)00264-9

ESMO 2025

Breast Cancer

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

EHA/ICML 2025

Myeloproliferative Neoplasms (MPNs)

Encouraging Results with First-In-Class Targeted Therapy in Essential Thrombocythemia

ESMO 2025

Breast Cancer

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

SABCS 2024

Breast Cancer

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

SABCS 2024

Breast Cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

ASH 2024

Lymphoma

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

Genitourinary Cancer

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Prostate

Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O

doi: 10.1002/pros.24855

Related content

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

Encouraging Results with First-In-Class Targeted Therapy in Essential Thrombocythemia

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer